CDK9 inhibition as a potential therapeutic strategy in Ewing sarcoma

被引：0
|
作者：
Matsumura, Yuta
Heinz, Richard E.
Allred, Curtis A.
Siddiqui, Adam
Foulks, Jason M.
Warner, Steven L.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-5984
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5984
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Inhibition of CDK9 as a therapeutic strategy for inflammatory arthritis
    Hellvard, Annelie
    Zeitlmann, Lutz
    Heiser, Ulrich
    Kehlen, Astrid
    Niestroj, Andre
    Demuth, Hans-Ulrich
    Koziel, Joanna
    Delaleu, Nicolas
    Potempa, Jan
    Mydel, Piotr
    SCIENTIFIC REPORTS, 2016, 6
  • [2] Inhibition of CDK9 as a therapeutic strategy for inflammatory arthritis
    Annelie Hellvard
    Lutz Zeitlmann
    Ulrich Heiser
    Astrid Kehlen
    André Niestroj
    Hans-Ulrich Demuth
    Joanna Koziel
    Nicolas Delaleu
    Piotr Jan Potempa
    Scientific Reports, 6
  • [3] CDK9 as a potential therapeutic target in sarcomas
    Matsumura, Yuta
    Umehara, Hiroki
    Oishi, Jun
    Siddiqui, Adam
    Foulks, Jason M.
    Yamamoto, Setsuko
    Warner, Steven L.
    CANCER RESEARCH, 2022, 82 (12)
  • [4] Transcriptional regulation and therapeutic potential of cyclin-dependent kinase 9 (CDK9) in sarcoma
    Walker, Robert L.
    Hornicek, Francis J.
    Duan, Zhenfeng
    BIOCHEMICAL PHARMACOLOGY, 2024, 226
  • [5] CDK9 Inhibition by Dinaciclib Is a Therapeutic Vulnerability in Epithelioid Hemangioendothelioma
    Pobbati, Ajaybabu V.
    Burtscher, Ashley
    Rajaram Siva, Nandini
    Hallett, Andrea
    Romigh, Todd
    Che, Kepeng
    Zhao, Bin
    Coker, Jesse A.
    Wang, Nancy
    Stauffer, Shaun R.
    Rubin, Brian P.
    CLINICAL CANCER RESEARCH, 2024, 30 (18) : 4179 - 4189
  • [6] Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
    Olson, Calla M.
    Jiang, Baishan
    Erb, Michael A.
    Liang, Yanke
    Doctor, Zainab M.
    Zhang, Zinan
    Zhang, Tinghu
    Kwiatkowski, Nicholas
    Boukhali, Myriam
    Green, Jennifer L.
    Haas, Wilhelm
    Nomanbhoy, Tyzoon
    Fischer, Eric S.
    Young, Richard A.
    Bradner, James E.
    Winter, Georg E.
    Gray, Nathanael S.
    NATURE CHEMICAL BIOLOGY, 2018, 14 (02) : 163 - +
  • [7] Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
    Olson C.M.
    Jiang B.
    Erb M.A.
    Liang Y.
    Doctor Z.M.
    Zhang Z.
    Zhang T.
    Kwiatkowski N.
    Boukhali M.
    Green J.L.
    Haas W.
    Nomanbhoy T.
    Fischer E.S.
    Young R.A.
    Bradner J.E.
    Winter G.E.
    Gray N.S.
    Nature Chemical Biology, 2018, 14 (2) : 163 - 170
  • [8] CDK9 inhibition for ATL therapy
    Bazarbachi, Ali
    BLOOD, 2017, 130 (09) : 1074 - 1075
  • [9] Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067
    Shen, Shen
    Deane, Dylan C.
    Yu, Zujiang
    Hornicek, Francis
    Kan, Quancheng
    Duan, Zhenfeng
    JOURNAL OF CANCER, 2020, 11 (01): : 132 - 141
  • [10] CDK9 inhibition strategy defines distinct sets of target genes
    Garriga J.
    Graña X.
    BMC Research Notes, 7 (1)
12345